Supernus Pharmaceuticals Details Executive Compensation Increases and Substantial Equity Grants
Summary
Supernus Pharmaceuticals announced annual base salary increases, 2025 bonuses, and significant equity grants for its executive officers, including the CEO and CFO, following an annual compensation review.
Key Events
-
Executive Compensation Increases
Annual base salaries for five executive officers, including the CEO and CFO, were increased by 3-4% effective January 1, 2026.
-
Significant Equity Grants
Executive officers received substantial equity awards, including 399,610 stock options, 12,000 restricted stock units (RSUs), and 218,966 performance share units (PSUs).
-
CEO Equity Award
CEO Jack A. Khattar was granted 341,610 stock options and 204,966 PSUs, with options having an exercise price of $50.20 per share.
-
Performance-Based Vesting
Stock option grants and RSU awards will vest annually in equal increments over a four-year period, while PSUs vest based on the achievement of specified performance goals.
Analysis
This 8-K details the annual compensation adjustments for Supernus Pharmaceuticals' executive team, including CEO Jack A. Khattar and CFO Timothy C. Dec. While base salary increases are modest (3-4%), the filing highlights substantial equity grants, particularly for the CEO, comprising stock options, restricted stock units (RSUs), and performance share units (PSUs). The total potential dilutive shares from these grants represent a significant portion of the current market capitalization. These grants are designed to incentivize long-term performance, with PSUs vesting based on specific performance goals. Investors should note the scale of these equity awards as they represent future potential dilution, even though they are part of a routine annual compensation review aligned with industry peer groups.
At the time of this filing, SUPN was trading at $55.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $29.16 to $57.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.